Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan PK in Renal Impairment
NCT03186495Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of somapacitan in growth hormone deficiency (GHD) (5 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the somapacitan serum concentration time curve. Started Jun 2017; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03186495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186495.